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Abstract
Aims Cardiovascular complications, including myocarditis, are observed in coronavirus disease 2019 (COVID‐19). Major
cardiac involvement is a potentially lethal feature in severe cases. We sought to describe the underlying pathophysiological
mechanism in COVID‐19 lethal cardiogenic shock.
Methods and results We report on a 48‐year‐old male COVID‐19 patient with cardiogenic shock; despite extracorporeal life
support, dialysis, and massive pharmacological support, this rescue therapy was not successful. Severe acute respiratory
syndrome coronavirus 2 RNA was detected at autopsy in the lungs and myocardium. Histopathological examination revealed
diffuse alveolar damage, proliferation of type II pneumocytes, lymphocytes in the lung interstitium, and pulmonary
microemboli. Moreover, patchy muscular, sometimes perivascular, interstitial mononuclear inflammatory infiltrates, domi-
nated by lymphocytes, were seen in the cardiac tissue. The lymphocytes ‘interlocked’ the myocytes, resulting in myocyte de-
generation and necrosis. Predominantly, T‐cell lymphocytes with a CD4:CD8 ratio of 1.7 infiltrated the interstitial myocardium,
reflecting true myocarditis. The myocardial tissue was examined for markers of ferroptosis, an iron‐catalysed form of regulated
cell death that occurs through excessive peroxidation of polyunsaturated fatty acids. Immunohistochemical staining with E06,
a monoclonal antibody binding to oxidized phosphatidylcholine (reflecting lipid peroxidation during ferroptosis), was positive
in morphologically degenerating and necrotic cardiomyocytes adjacent to the infiltrate of lymphocytes, near arteries, in the
epicardium and myocardium. A similar ferroptosis signature was present in the myocardium of a COVID‐19 subject without
myocarditis. In a case of sudden death due to viral myocarditis of unknown aetiology, however, immunohistochemical staining
with E06 was negative. The renal proximal tubuli stained positively for E06 and also hydroxynonenal (4‐HNE), a reactive break-
down product of the lipid peroxides that execute ferroptosis. In the case of myocarditis of other aetiology, the renal tissue
displayed no positivity for E06 or 4‐HNE.
Conclusions The findings in this case are unique as this is the first report on accumulated oxidized phospholipids (or their
breakdown products) in myocardial and renal tissue in COVID‐19. This highlights ferroptosis, proposed to detrimentally
contribute to some forms of ischaemia–reperfusion injury, as a detrimental factor in COVID‐19 cardiac damage and multiple
organ failure.
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FIGURE 1 (A) Chest CT. The coronal image shows multiple patchy ground‐glass opacifications in all lung fields (right more than left) (Illness Day 7,
Hospital Day 1). (B) Electrocardiogram on Day 5 after admission showing a widened QRS in the absence of hypokalaemia (Illness Day 11,
Hospital Day 5).
Introduction
The ongoing severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) pandemic is responsible for a great many
cases of respiratory syndrome coronavirus disease 2019
(COVID‐19), which is characterized by respiratory distress
with radiological and clinical features resembling full‐blown
acute respiratory distress syndrome (ARDS).1 Recently, atten-
tion has been drawn to the cardiac complications of this dis-
ease. Amongst hospitalized COVID‐19 patients, some form of
cardiac injury is seen in up to 27,8 %,2 as evidenced by a rise
in cardiac troponin I (TnI) serum levels.2 Major cardiac in-
volvement is a potentially lethal feature in severe COVID‐19.
Fulminant myocarditis, an acute rapidly progressive
form of myocardial failure caused by infectious and
non‐infectious agents and in systemic diseases, is character-
ized and accompanied by marked inflammation and has a
poor in‐hospital outcome.3 The diagnosis of fulminant myo-
carditis is based on clinical suspicion and can be confirmed
by endomyocardial biopsy. In view of the marked inflamma-
tion seen in COVID‐19 patients and the apparently very poor
prognosis of cardiac failure in young patients, myocarditis
rather than ischaemic cardiogenic shock has been proposed
as the underlying mechanism in some cases of COVID‐19
related cardiac injury; nevertheless, there is little published
data about the underlying pathologic mechanisms that might
cause this type of cardiac failure to occur in COVID‐19
patients.
Case report
On 21March 2020, a 48‐year‐old man presented at a regional
hospital with a 7‐day history of fever, diarrhoea, cough,
dysosmia, and dyspnoea. His medical history was uneventful
apart from hypertension, for which he took an angiotensin II
receptor blocker daily. Initially, oxygen saturation was 87%
without oxygen, and his body temperature was 38.6°C; the
electrocardiogram revealed no abnormalities. Rapidly pro-
gressive shortness of breath and hypoxaemia necessitated in-
tubation within hours, as well as prone ventilation to achieve
sufficient oxygenation, which at that time resulted in a decline
in the amount of oxygen needed (Fi02 of 55%). Polymerase
chain reaction on both the nasopharyngeal aspirate and a
throat swab was positive for SARS‐CoV‐2 RNA. Other viruses
(cytomegalovirus, herpes simplex virus, adenovirus, and
parainfluenza virus) were also tested for but turned out
negative. A chest computed tomography showed typical
pneumonia, as seen in COVID‐19 infection (Figure 1A).
Hydroxychloroquine and azithromycin were administered.
Rapidly progressive acute kidney injury with anuria necessi-
tated continuous venovenous hemofiltration. Lung protective
ventilation in an airway pressure release ventilation mode was
applied. In the afternoon of Day 12 of its illness, 5 days after
hospital admission (26March), there was a rapidly progressive
lactic acidosis and shock, necessitating vasopressors and ino-
tropics (noradrenaline, adrenaline, and dobutamine). Labora-
tory tests showed an increase of the troponin I level from 12.1
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on admission to 14 932 ng/L (normal value < 45 ng/L) (Table 1).
Echocardiography showed a hyperdynamic ventricular func-
tion, although under massive support of inotropic agents
and vasopressors. No significant valvular pathology was seen.
Pulmonary pressures could not be measured (in absence of a
tricuspid insufficiency). An interventricular septum dimension
of 12mm and posterior wall dimension of 11mmwere noted.
The left ventricular end diastolic diameter was 48 mm. There
was no pericardial effusion. His lymphocyte count had been
low at admission (300 μL1) and remained low during the
whole hospitalization (Table 1). Broad‐spectrum antibiotics
were added to cover sepsis, and hydrocortisone 100 mg t.i.
d. was administered in view of the massive shock. Electrocar-
diography findings showed marked QRS widening and a posi-
tive deflection at the end of the T wave in the absence of
hypokalaemia (Figure 1B). Given the suspicion of myocarditis
and the deep shock, venoarterial extracorporeal membrane
oxygenation was installed on the scene by the extracorporeal
membrane oxygenation team of the Antwerp University Hos-
pital; the patient was then transported by this team to the in-
tensive care unit of this tertiary referral hospital. At this time,
the patient’s ferritin levels were massively elevated: the
initial level of 1200 μg/L rose up to 32 401 μg/L (normal
value < 322 μg/L) and was accompanied by severe
hypertriglyceridaemia (481 mg/dL, normal < 120 mg/dL).
The serum interleukin 6 level was 281 pg/mL
(normal < 7 pg/mL). The N terminal pro brain natriuretic pep-
tide level as a marker of cardiac failure was 9223 pg/mL
(normal < 125 pg/mL). Culture of endotracheal aspirate and
blood cultures in both hospitals did not reveal any accompa-
nying bacterial infection. Despite the extracorporeal life sup-
port, dialysis, and massive pharmacological support, this
rescue therapy was not successful: there was an absence of
any pulsatility in the arterial waveform, and the patient died
due to refractory shock on 27 March 2020.
As there is a dearth of published pathology data on the un-
derlying physiopathology of organ failure and death in
COVID‐19 are similarly lacking, a clinical autopsy was per-
formed after receiving permission from the patient’s family.
External examination showed an overweight adult male
patient. Citrine‐coloured pleural fluid was present in both
thoracic cavities. The lungs (left 1498 g, right 1635 g) were
purplish, edematous, with a mottled aspect (Figure 2A). The
pericardial sac was filled with yellow citrine‐coloured fluid.
The heart was hypertrophic (605 g) with widened right and
left ventricles and thickened ventricle walls (left 15 mm, sep-
tum 14 mm, and right 6 mm). On the outer wall of the left
ventricle and the endocardium, some petechiae were noticed
(Figure 2B). The coronaries were perfectly passable without
atherosclerosis. The cut surface did not show macroscopic
particularities. Ascites fluid was present in the abdominal
cavity. The kidneys showed signs of acute kidney injury. The
spleen (358 g) showed multiple infarctions without
thromboemboli.
Microscopically, diffuse alveolar damage with intra‐
alveolar and interstitial oedema and denudation of the alveo-
lar epithelium with hyaline membrane formation was ob-
served in both lungs, indicating ARDS. Re‐epithelialization
with proliferation of type II pneumocytes was also found in
several zones (Figure 3). Multinucleated cells were also iden-
tified (Supporting Information, Figure S1). The epithelial cells
showed striking reactive cytonuclear changes with polymor-
phic nuclei and prominent nucleoli. No obvious intranuclear
or intracytoplasmic viral inclusions were identified. Intersti-
tially, there were diffuse inflammatory infiltrates, dominated
by lymphocytes. Only mild neutrophilic inflammation was
present. We also report on multiple peripheral pulmonary
arterial microemboli in both lungs (Figure 3, insert), which
might reflect the procoagulant profile as well as microangiop-
athy seen in COVID‐19 patients making them prone to throm-
boembolic complications in large as well as small alveolar
capillary vessels.4
Histopathological examination showed hypertrophic
cardiac tissue with patchy muscular, sometimes perivascular,
and slightly diffuse interstitial mononuclear inflammatory in-
filtrates, dominated by lymphocytes (Figure 4). No throm-
botic events were observed in the microcirculation of the
heart. In the patchy areas, the lymphocytes ‘interlocked’
the myocytes, resulting in myocyte degeneration and necro-
sis (piecemeal necrosis). Intermingled with lymphocytes, only
a very few individual polymorphous neutrophils were found
in the affected areas. Signs of inflammation were present in
both the epicardium and the myocardium. By immunohisto-
chemistry, the lymphocytes were positive with CD3, CD4,
CD8, and a small number of CD20. In the largest inflamma-
tory infiltrate, 92% of the lymphocytes were CD3 + T
Table 1 Evolution of laboratory results
21.03.20 22.03.20 23.03.20 24.03.20 25.03.20 26.03.20 27.03.20 Normal values
WBC (×103/μL) 10.6 12.5 25.6 19.4 11.0 12.4 14.6 3.9–10.6
Lymphocytes (×103/μL) 0.30 0.26 0.26 0.35 MD 0.45 0.77 1.00–4.80
D‐dimers (μg/L) 611 MD MD MD MD MD MD 0–549
Troponin I (ng/L) 12.1 12.2 143.2 97.7 59.2 108.4 14 932 0.0–34.2
CRP (mg/L) 247.1 340.9 462 547.7 472.5 441.9 318 <5.0
Ferritin (μg/L) 1200 MD MD MD MD MD 32 401 <322
INR MD MD 1.06 1.04 1.05 1.15 1.15 0.9–1.2
CRP, C‐reactive protein; INR, international normalized ratio; MD, missing values; WBC, white blood cells.
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lymphocytes, and 8% were CD20 + B lymphocytes. The CD4:
CD8 ratio was 1.7. These findings indicate a predominant
T‐cell phenotype of the cardiac inflammatory infiltrate.
Intermingled, there was limited number of CD68‐positive
macrophages. CD138 showed a few plasma cells. As no inter-
stitial fibrosis disarray of the muscle fibres was seen, true
preexisting cardiomyopathy could be excluded.
The spleen showed a disturbed architecture with multiple
recently infarcted zones without thromboemboli. In the
kidneys, a striking amount of intratubular oxalate crystals
was found. There was also a slight presence of interstitial in-
flammation in the kidneys and signs of acute tubular necrosis.
Furthermore, organ damage in the liver was observed in the
context of shock.
FIGURE 3 Lung tissue with diffuse alveolar damage, with hyaline formation (arrow), marked type 2 pneumocyte hyperplasia (asterisk) with prominent
nucleoli and multinucleation and interstitial mononuclear inflammatory infiltrates (predominantly with lymphocytes) (original magnification ×100). In-
sert: microembolus.
FIGURE 2 Macroscopy at autopsy. (A) The lungs were purplish, edematous, and had a mottled aspect. (B) View on the left ventricle with some pete-
chiae in the endocardium.
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Molecular detection of SARS‐CoV‐2 in the samples (heart
and lung biopsy, endotracheal and nasopharyngeal aspirate)
was done by targeting the SARS‐CoV‐2 envelope (E)‐gene ac-
cording to a World Health Organization recommended
protocol.5 The cycle threshold (Ct) value for the E‐gene and
corresponding viral load (log10 RNA copies/mL) were 28.94/
5.6 (nasopharyngeal aspirate), 31.22/4.9 (endotracheal aspi-
rate), 23.44/7.4 (lung biopsy), 35.90/3.5 (pericardial swab),
and 31.53/4.9 (heart biopsy). Additional confirmatory testing
was performed on the heart biopsy by targeting the SARS‐
CoV‐2 nucleocapside (N) gene according to the Centers for
Disease Control and Prevention protocol (N1 and N3).6 The
Ct values for the N‐gene in the heart biopsy were 31.74
(N1) and 31.64 (N3).
Ferroptosis signature
We examined the patient’s myocardial tissue for markers of
ferroptosis, an iron‐catalysed form of regulated cell death
that occurs through excessive peroxidation of polyunsatu-
rated fatty acids and is also proposed to detrimentally
contribute to some forms of ischaemia–reperfusion injury,
FIGURE 4 Histochemical and immunohistochemical examination of a heart tissue sample (several sections of the heart performed: septum n ¼ 2, an-
terior wall n ¼ 2, posterior wall n¼ 2, right ventricle n¼ 1). Lymphocytes infiltrating the cardiomyocytes (A–C), resulting in myocyte degeneration and
necrosis (D). Most of the lymphocytes are CD3‐positive (B) and CD4‐positive (C) T‐cells. The CD4‐positive cells progressively infiltrate the
cardiomyocytes (C) demonstrated by the progressive disappearance of the desmin‐positive myofibrils (brown in panel D) and are accompanied with
only a few CD68‐positive macrophages (E). Staining: HE (A), CD3 (B), CD4 (C), desmin (D), and CD68 (E). Original magnification: ×50 (A, B) and
×200 (C, D).
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stroke, and degenerative diseases.7 Immunohistochemical
staining with E06 (Figure 5A), a monoclonal antibody binding
to oxidized phosphatidylcholine (reflecting lipid peroxidation
during ferroptosis), was positive in morphologically
degenerating and necrotic cardiomyocytes adjacent to the
infiltrate of lymphocytes.8,9 E06 positivity was also found
near arteries, in the epicardium and myocardium. Note a
gradient‐like staining, reflecting a wave of synchronized
necrosis, as has been reported to occur for ferroptosis.10 This
specific myocardial immunodetection of abundant lipid per-
oxides with E06 antibody was replicated several times on in-
dependent staining procedures. Of note, in a case of
sudden death due to viral myocarditis of unknown aetiology,
immunohistochemical staining with E06 was negative (Figure
5B). The hypertrophic myocardium of a deceased COVID‐19
patient with severe ARDS, but without cardiac failure/
myocarditis, showed only small foci of E06 positivity
throughout the ventricular wall (Figure 5C). The myocardium,
also obtained at autopsy, of a COVID‐19 subject without myo-
carditis (after sudden death due to trauma) did not show this
prominent signature for E06 (Figure 5D).
In order to elucidate the role of ferroptosis during multiple
organ dysfunction syndrome (MODS)11 including cardiac and
renal failure in this patient, immunohistochemical staining
was performed on renal tissue using E06 and anti‐4‐
hydroxynonenal (HNE) antibody. 4‐HNE is a highly reactive
breakdown product of the lipid peroxides that execute
ferroptosis.11 Renal tissue of the COVID‐19 patient with lym-
phocytic myocarditis stained positively for both E06 and
4‐HNE in the cortical region. More precisely, these ferroptosis
markers are detected in the proximal tubuli (Figures 6A and
6C). In the case of sudden death due to myocarditis of other
aetiology, the morphologically normal renal tissue displayed
no positivity for E06 or 4‐HNE (Figures 6B and 6D, respec-
tively). Attempts to stain lung tissue failed due to high back-
ground staining from multiple lung haemorrhages.
Discussion
At the time of writing, there are few published autopsy find-
ings in COVID‐19 patients, where damage mostly of the lungs
is reported but not of the heart tissue.12–14 It was described
that a few mononuclear cells had infiltrated the interstitium
of the heart.14,15 Viral particles and low‐grade interstitial in-
flammation with vacuolated CD68‐positive macrophages
were observed in the endomyocardial biopsy of patients with
COVID‐19 related cardiogenic shock.15–17 Recently, (low loads
of) SARS‐COV‐2 genomes have been detected in the
FIGURE 5 Immunohistochemical examination of heart tissue for a ferroptosis marker. E06 immunoreactivity (protocol adapted from Haider et al.9) was
detected in the area of severe SARS‐CoV‐2 myocarditis, near arteries and throughout the myocardium in a gradient‐like manner (A). In a case of a
16‐year‐old man who suddenly died of non‐COVID‐19 myocarditis due to other aetiology, no signal was detected on staining with E06 (B). The myo-
cardium of a 33‐year‐old male COVID‐19 patient that succumbed to severe acute respiratory distress syndrome and multiple organ failure, but without
myocarditis, showed foci of E06 positivity in all areas of the ventricular wall and perivascular regions (C). The myocardium of another control subject
without myocarditis, a 48‐year‐old man who was hospitalized after trauma, showed only some E06 positivity in perivascular connective tissue
(D). Control stains using only secondary antibodies are available in the Supporting Information.
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endomyocardial biopsies of 5 out of 104 patients with
suspected myocarditis or unexplained heart failure.18 In one
patient, histological analysis revealed an active myocarditis
with vessels involved in the inflammation process and accom-
panying necrosis of myocytes; in the four others, predomi-
nantly, T‐cells (as stained by a CD3 antibody) were found.18
We provide the first in‐depth histopathological description
of a histology‐proven fatal case of SARS‐CoV‐2 viral myocardi-
tis in a COVID‐19 patient with cardiogenic shock together
with overt respiratory failure. The findings fulfil the histolog-
ical, immunohistochemical, and microbiological criteria for
definite lymphocytic, myocarditis of viral origin: interstitial,
principally CD3‐positive, T‐lymphocytic infiltration associated
with myocyte damage.19 The COVID‐19 causality is supported
by reverse transcriptase polymerase chain reaction amplifica-
tion of the viral genome in myocardial tissue. Moreover, lym-
phocytes are hardly found in the myocardium of patients
dying of septic shock, therefore supporting that the cardiac
damage seen in this patient is most probably due to lympho-
cytic myocarditis; in the case of full‐blown septic myocarditis,
polynuclear granulocytes would be present. The diagnosis in
several previous case reports on fulminant myocarditis due
to COVID‐19 has been based on clinical signs only.20,21
Our data give a unique insight into the physiopathogenesis
of COVID‐19 related cardiac failure and MODS. The
immunohistochemical marker (presence of oxidized
phosphatidylcholine) for ferroptosis was positive in myocar-
dial tissue from this COVID‐19 related lymphocytic myocardi-
tis and of a case of fatal COVID‐19 without myocarditis.
Indeed, this COVID‐19 patient with lymphocytic myocarditis
presented also with refractory shock and multiple organ dys-
function necessitating renal replacement therapy. Microscop-
ically, the renal tissue too displayed signs of acute tubular
necrosis, intratubular oxalate crystals, and abundant pres-
ence of oxidized phosphatidylcholine and also 4‐HNE in the
proximal tubules.
Ferroptosis has been conceptualized in 2012 as a novel
type of regulated cell death.22 This form of regulated necrotic
cell death is mediated by iron‐catalysed lipid peroxides that
compromise the plasma membrane integrity. The abundance
of lipid peroxides in myocardium and renal cortex of the
COVID‐19 patient with lymphocytic myocarditis might also
be related to ischaemia and ischaemia–reperfusion injury in
these organs as seen in MODS.7,10 Indeed, such insults cause
an increased production of radical oxygen species by, for ex-
ample, the mitochondrial respiratory chain that could subse-
quently attack polyunsaturated fatty acids, leading to lipid
peroxides that execute ferroptosis. In preclinical models,
ferroptosis has been implicated in ischaemia–reperfusion in-
jury of the myocardium, kidney, liver, intestine, and brain.10
Based on our data, it is tempting to suggest that ferroptosis
is a detrimental factor in organ injury during shock and MODS
FIGURE 6 Immunohistochemical examination of renal tissue for potential ferroptosis markers. Renal tissue from the COVID‐19 patient with myocar-
ditis and multiple organ dysfunction syndrome showed morphological signs of acute tubular necrosis, intratubular oxalate crystals, as well as E06 pos-
itivity in proximal tubuli (A). The latter also stained positively for the presence of 4‐HNE, one of the breakdown product of lipid peroxides (protocol
adapted from Feng et al.
11
) (C). By comparison, in the case of sudden death due to myocarditis of other aetiology, immunohistochemical staining with
E06 (B) and anti‐4‐HNE antibody (D) in the renal tissue showed no presence of these ferroptosis markers (non‐specific staining in the corticomedullary
junction is also present on control stains). Control stains using only secondary antibodies are enclosed in the Supporting Information.
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and COVID‐19 lymphocytic myocardial infiltration. The car-
diac damage observed in the heart might therefore be multi-
factorial, related to direct invasion of the virus, acid–base
imbalance due to kidney injury, hypoxaemia due to
respiratory failure as well as ischaemia–reperfusion related
ferroptosis due to the severe cardiogenic shock.
Severe acute respiratory syndrome coronavirus 2 was de-
tected in the heart of 35% of those that died from SARS,23
with the authors concluding that coronaviruses such as
SARS‐CoV are able to infect and invade the myocardium. At
that time, myocardial inflammation caused by SARS‐CoV
was believed to be predominantly mediated by
macrophages,23 while we additionally show a prominent role
for T‐lymphocytes in COVID‐19. In SARS‐infected human
cases, marked production of oxidized phospholipids in the in-
flammatory exudates lining the injured air spaces,
pneumocytes, and alveolar macrophages had already been
shown,24 as we show here too in the myocardium and renal
tissue as part of the ferroptosis process.
In this patient, as in many other COVID‐19 patients with or
without myocarditis, extreme hyperferritinemia accompanied
by a cytokine ‘storm’ was seen.25 Likewise, the patient’s myo-
cardial tissue showed an increased signal for ferritin espe-
cially in the epicardial region (data not shown). Ferritin is
known to be a pro‐inflammatory mediator inducing expres-
sion of pro‐inflammatory molecules26; the high ferritin levels
observed in these uncommon clinical conditions (sepsis,
myocarditis, etc.) are therefore not just the product of the
inflammation but rather may contribute to the development
of a cytokine storm therefore considered a form of
‘hyperferritinemic syndrome’.27 Our group (and others) has
shown that exuberant ferroptosis produces high amounts of
ferrous iron that could exceed the buffering capacity of
ferritin.28 The unbuffered, free ferrous iron catalyses radical
oxygen species via Fenton reactions and hence lipid perox-
ides. Along with the cytokine storm and inflammation, this
iron dysbiosis might thus also contribute to the
hyperferritinemia observed in severe COVID‐19 patients. It
has been noted that iron dysbiosis, including an increase in
plasma ferrous iron and ferritin, also associates with death
in critically ill patients with severe acute kidney injury.29
In view of the absence of any superimposed infection, ful-
minant myocarditis was retained as the most plausible diag-
nosis. More studies are needed to estimate the incidence of
SARS‐CoV‐2 viral myocarditis, although a definite diagnosis
on clinical—rather than pathological—data will remain diffi-
cult. In an era of high‐tech medicine, the autopsy still plays
an important role in unravelling the pathophysiology of
emerging infectious diseases. In anticipation of the develop-
ment of effective antiviral therapy, the attenuation of the cy-
tokine storm (e.g. with interleukin 6 receptor blockers) is
currently being studied; it remains to be determined if
ferroptosis inhibition alone might also be helpful in the treat-
ment of SARS‐CoV‐2 organ failure, including viral myocarditis.
Highly potent ferroptosis inhibitors might be promising leads
for clinical validation.30
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Figure S1. Detail of lung microscopy: multinuclear cells. (HE,
original. magnification. 200x).
Figure S2. negative controls of immunohistochemical staining
for the ferroptosis marker E06 in myocardium.
Control stains using only secondary antibodies showed no sig-
nificant signal in the COVID‐19 related myocarditis case
(Panel A), nor in patients with sudden death due myocarditis
of other etiology (Panel B) or the COVID‐19 patient without
myocarditis (Panel C). Likewise, no significant signal was de-
tected in the myocardium of a control subject without myo-
carditis or COVID‐19 after staining with only the secondary
antibody (Panel D).
Figure S3. negative controls of immunohistochemical staining
for the ferroptosis markers EO6 and 4‐HNE in renal tissue.
Staining with only the secondary antibodies from the staining
protocols of E06 (Panel A) and anti‐4HNE antibody (Panel C)
showed a limited signal at the corticomedullary region. In
the renal tissue of a case of sudden death due to myocarditis
of other etiology a nonspecific signal was detected in the
corticomedullary region after staining with these secondary
antibodies (Panel B and D).
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